Last reviewed · How we verify
Autologous Fecal Microbiota Transplantation
Autologous Fecal Microbiota Transplantation is a Small molecule drug developed by MaaT Pharma. It is currently in Phase 2 development for Moderate to severe Clostridioides difficile infection, Ulcerative colitis. Also known as: MaaT011.
Autologous Fecal Microbiota Transplantation involves transplanting a patient's own fecal microbiota to restore a balanced gut microbiome.
Autologous Fecal Microbiota Transplantation involves transplanting a patient's own fecal microbiota to restore a balanced gut microbiome. Used for Moderate to severe Clostridioides difficile infection, Ulcerative colitis.
At a glance
| Generic name | Autologous Fecal Microbiota Transplantation |
|---|---|
| Also known as | MaaT011 |
| Sponsor | MaaT Pharma |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 2 |
Mechanism of action
This procedure aims to restore a healthy balance of gut bacteria, which can be disrupted by various factors such as antibiotics, diet, or disease. By transplanting the patient's own fecal microbiota, the goal is to promote a diverse and resilient gut microbiome that can help maintain overall health and prevent disease.
Approved indications
- Moderate to severe Clostridioides difficile infection
- Ulcerative colitis
Common side effects
- Abdominal pain
- Diarrhea
- Nausea
- Vomiting
Key clinical trials
- Transfer of Feces in Ulcerative Colitis 2 (PHASE2)
- Efficacy and Safety of Auto-FMT in Preventing aGVHD (NA)
- Autologous Fecal Microbiota Transplantation (Auto-FMT) for Prophylaxis of Clostridium Difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation (PHASE2)
- Fecal Microbiota Transplantation for IBS (PHASE2)
- Faecal Autologous Capsule Transplantation for Type 1 Diabetes Mellitus (PHASE2)
- Effect of Fecal Microbiota Transfer on Progression of Parkinson Disease (PHASE2)
- Stool Transplantation for Treatment of Insulin Resistance in Morbidly Obese Patients (PHASE2)
- FMT in Obesity: RYGB vs. LEAN vs. Autologous FMT (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Autologous Fecal Microbiota Transplantation CI brief — competitive landscape report
- Autologous Fecal Microbiota Transplantation updates RSS · CI watch RSS
- MaaT Pharma portfolio CI
Frequently asked questions about Autologous Fecal Microbiota Transplantation
What is Autologous Fecal Microbiota Transplantation?
How does Autologous Fecal Microbiota Transplantation work?
What is Autologous Fecal Microbiota Transplantation used for?
Who makes Autologous Fecal Microbiota Transplantation?
Is Autologous Fecal Microbiota Transplantation also known as anything else?
What development phase is Autologous Fecal Microbiota Transplantation in?
What are the side effects of Autologous Fecal Microbiota Transplantation?
Related
- Manufacturer: MaaT Pharma — full pipeline
- Therapeutic area: All drugs in Gastroenterology
- Indication: Drugs for Moderate to severe Clostridioides difficile infection
- Indication: Drugs for Ulcerative colitis
- Also known as: MaaT011
- Compare: Autologous Fecal Microbiota Transplantation vs similar drugs
- Pricing: Autologous Fecal Microbiota Transplantation cost, discount & access